---
title: "Nomura Adjusts Akeso's Price Target to HK$112.73 From HK$120.64, Keeps at Neutral"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277909219.md"
description: "Nomura Adjusts Akeso's Price Target to HK$112.73 From HK$120.64, Keeps at Neutral"
datetime: "2026-03-05T09:10:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277909219.md)
  - [en](https://longbridge.com/en/news/277909219.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277909219.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277909219.md) | [繁體中文](https://longbridge.com/zh-HK/news/277909219.md)


# Nomura Adjusts Akeso's Price Target to HK$112.73 From HK$120.64, Keeps at Neutral



### Related Stocks

- [AKESO (09926.HK)](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [Akeso's Ivonescimab Shows Strong Phase 3 Results in Lung Cancer Trial](https://longbridge.com/en/news/261967652.md)
- [The Bull Case For Akeso (SEHK:9926) Could Change Following FDA Clearance Of Global Gastric Cancer Trial](https://longbridge.com/en/news/269971630.md)
- [Macquarie Downgrades Prada to Neutral from Outperform, Price Target is HK$46](https://longbridge.com/en/news/278094455.md)
- [Nomura Adjusts RemeGen's Price Target to HK$79.64 From HK$47.60, Keeps at Neutral](https://longbridge.com/en/news/277909143.md)
- [Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$438.30 From HK$434.36, Keeps at Buy](https://longbridge.com/en/news/277909187.md)